Drugs / BI 1467335
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT03979820 | Jul 2019 → Apr 2020 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT03927209 | Jun → Nov 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03483506 | Apr → Jun 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03382509 | Jan → Apr 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03302091 | Oct 2017 → Aug 2018 | impaired renal function disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03159455 | Jun → Dec 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02999191 | Jan → Mar 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02733627 | Jul 2016 → Jul 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03238963 | Sep 2017 → May 2020 | diabetic retinopathy | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT03166735 | Jun 2017 → Jun 2019 | NAFLD1 | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1467335 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02733627 ↗ |
| Action | Inhibit | “These changes indicated that BI 1467335 dose-dependently inhibited AOC3 activity” PMID 37932258 ↗ Nov 2023 |
| Route | Oral | “following oral administration” NCT02733627 ↗ |
| Target | AOC3 | “an amine oxidase copper-containing 3 (AOC3) inhibitor” PMID 37932258 ↗ Nov 2023 |